Good
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanistic and hypertension-use statements are consistent with the provided label excerpts, and kidney function/potassium monitoring align with warnings. However, several claims are either unsupported by the supplied label sections (e.g., class comparison/avoidance in pregnancy wording, generic availability) or not fully supported as stated (e.g., dizziness/lightheadedness claim not explicitly in the excerpts).
Category Scores
Accurate Statements
Benicar is a brand of olmesartan.
Provided label excerpts describe olmesartan medoxomil (Benicar) and olmesartan as the active moiety; label text is consistent with Benicar containing olmesartan medoxomil.
Olmesartan (Benicar) is an angiotensin II receptor blocker (ARB).
Mechanism of action excerpt: olmesartan selectively blocks binding of angiotensin II to the AT1 receptor.
Benicar is used to treat high blood pressure (hypertension) in adults.
Section 1 INDICATIONS AND USAGE: Benicar indicated for treatment of hypertension in adults.
Benicar works by relaxing blood vessels so the heart can pump more easily.
Mechanism excerpt: blocks vasoconstrictor effects of angiotensin II (via AT1 blockade). (The heart-pumping framing is not explicitly in the excerpt, but vasodilation/vascular effects are supported.)
Benicar is part of the same drug class as other ARBs such as valsartan, losartan, and irbesartan.
Label excerpt supports that olmesartan is an angiotensin II AT1 receptor antagonist; it does not name other ARBs, so class grouping is inferential but consistent with the ARB description.
ARBs target the renin-angiotensin system through the angiotensin II receptor.
Mechanism excerpt: blockade of angiotensin II receptor inhibits renin-angiotensin system effects (AT1 receptor blockade).
ARBs like Benicar can affect kidney function.
Warnings excerpt 5.4 Impaired Renal Function: changes in renal function may be anticipated in susceptible individuals treated with Benicar.
ARBs like Benicar can affect potassium levels.
Warnings excerpt 5.6 Hyperkalemia: serum potassium should be monitored; drugs that inhibit the renin-angiotensin system can cause hyperkalemia.
Clinicians may monitor labs (kidney function and potassium levels) when using ARBs like Benicar.
5.4 discusses renal function changes; 5.6 explicitly states serum potassium should be monitored.
ARBs may be prescribed alone or in combination with other classes of antihypertensive drugs.
Section 1 INDICATIONS AND USAGE: 'It may be used alone or in combination with other antihypertensive agents.'
Benicar contains olmesartan.
DESCRIPTION excerpt: olmesartan medoxomil is hydrolyzed to olmesartan; Benicar tablets contain olmesartan medoxomil.
Clinicians commonly monitor kidney function and electrolytes (especially potassium) after starting or changing the dose of Benicar.
5.4 and 5.6 support monitoring; however, the excerpt provided does not explicitly restrict or specify 'after starting or changing the dose' for renal function—potassium monitoring is clearly indicated, but timing is not explicitly stated in the provided text.
Unsupported Statements
ARBs like Benicar may cause dizziness or lightheadedness, especially when starting or after dose changes.
The provided label excerpts include hypotension risk in volume-/salt-depleted patients and related management, but do not explicitly state dizziness/lightheadedness or timing ('especially when starting or after dose changes').
Olmesartan (the active ingredient in Benicar) is available as generics in many markets.
No information about generic availability is present in the supplied prescribing information excerpts.
ARBs are generally avoided in pregnancy or if a patient may become pregnant.
The pregnancy section content is not provided (only the heading '8.1 Pregnancy' is present). The statement cannot be confirmed against the supplied label text.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The claim list omits the provided label’s pediatric age indication nuance (children six years of age and older) and the label’s cardiovascular risk-reduction context (reduces risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions; no controlled trials demonstrating risk reduction with Benicar).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Key safety-relevant points included in the excerpts (renal function changes and hyperkalemia monitoring; hypotension in volume-/salt-depleted patients) were generally aligned, but some adverse-experience and pregnancy guidance were not supported by the supplied label text, reducing confidence.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
A few statements are not supported by the provided label excerpts (dizziness/lightheadedness, pregnancy avoidance, generic availability), and one monitoring timing statement is not explicitly supported for renal function in the excerpt.
Suggested Improvement
Remove or rephrase unsupported claims unless the full label text for those topics is provided (e.g., pregnancy section details; specific adverse reaction/dizziness statements; explicit timing for monitoring). Keep mechanistic, indication, and hyperkalemia/renal-function-alteration statements tied to the supplied label excerpts.